Primary mitral regurgitation (MR) is the most common heart valve pathology affecting 2% of the general population and is associated with decreased mid- and long-term survival rates. In the US alone, 2 million patients suffer from MR and that number is expected to double by 2030.
Minimally invasive, catheter based solutions, exist but they suffer from various limitations including procedural complexity, large bulky implants, and inability to subsequently treat patients with other devices.
Adjust Medical SA has developed the "AdjusTer": A small, form factor, device that aims to become the world's smallest MR implant to safely and effectively treat MR via a minimally invasive out-patient procedure without eliminating subsequent treatment options.
Minimally invasive, catheter based solutions, exist but they suffer from various limitations including procedural complexity, large bulky implants, and inability to subsequently treat patients with other devices.
Adjust Medical SA has developed the "AdjusTer": A small, form factor, device that aims to become the world's smallest MR implant to safely and effectively treat MR via a minimally invasive out-patient procedure without eliminating subsequent treatment options.